These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS Blood; 1995 Apr; 85(7):1727-35. PubMed ID: 7535586 [TBL] [Abstract][Full Text] [Related]
14. Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. Lichtman SM; Brody J; Kaplan MH; Susin M; Koduru P; Goh JC Leuk Lymphoma; 1993 Mar; 9(4-5):393-8. PubMed ID: 7688628 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. Straus DJ; Huang J; Testa MA; Levine AM; Kaplan LD J Clin Oncol; 1998 Nov; 16(11):3601-6. PubMed ID: 9817281 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan. Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129 [TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771 [TBL] [Abstract][Full Text] [Related]
18. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Filipits M; Jaeger U; Simonitsch I; Chizzali-Bonfadin C; Heinzl H; Pirker R Clin Cancer Res; 2000 Sep; 6(9):3417-23. PubMed ID: 10999723 [TBL] [Abstract][Full Text] [Related]
20. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]